Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases

Autor: Tea Lamberg, Taina Sipponen, Sanna Valtanen, Kari K Eklund, Tarja Mälkönen, Kristiina Aalto, Katriina Mikola, Kaija-Leena Kolho, Sanna Leinonen, Pia Isomäki, Heidi Mäkinen, Krista-Liisa Vidqvist, Arto Kokko, Laura Huilaja, Minna Kyllönen, Paula Keskitalo, Sirja Sard, Paula Vähäsalo, Ritva Koskela, Liisa Kröger, Perttu Lahtinen, Anna-Maija Haapala, Katja Korkatti, Tuulikki Sokka-Isler, T. Sakari Jokiranta
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Autoimmunity, Vol 55, Iss 5, Pp 275-284 (2022)
Druh dokumentu: article
ISSN: 0891-6934
1607-842X
08916934
DOI: 10.1080/08916934.2022.2067985
Popis: Introduction The prevalence of immune-mediated diseases has increased in the past decades and despite the use of biological treatments all patients do not achieve remission. The aim of this study was to characterise the reasons for short interruptions during treatment with two commonly used TNF-inhibitors infliximab and adalimumab and to analyse the possible effects of the interruptions on immunisation and switching the treatment. Material and methods This case-control study was based on retrospective analyses of patient records and a questionnaire survey to clinicians. A total of 370 patients (194 immunised cases and 172 non-immunised controls, 4 excluded) were enrolled from eight hospitals around Finland. Eleven different diagnoses were represented, and the largest patient groups were those with inflammatory bowel or rheumatic diseases. Results Treatment interruptions were associated with immunisation in patients using infliximab (p
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje